FDA Publishes Draft Guidance on Human Cellular and Gene Therapy Products
The document’s recommendations outline what studies and reports are required for changes to cell and gene therapy manufacturing.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - Artur - stock.adobe.com
FDA published a draft guidance document on July 13, 2023 outlining recommendations for manufacturing of products related to human cellular therapy or gene therapy (CGT). Recommendations included product compatibility and manufacturing changes regarding investigational and licensed CGT products. The draft guidance document reflected FDA’s current view on “management and reporting of manufacturing changes for CGT products based on a lifecycle approach, and comparability studies to assess the effect of manufacturing changes on product quality.”
The guidance specifically talks about considerations for the management of manufacturing changes related to risk management, stability and delivery device compatibility, nonclinical studies, and clinical students. It then covers regulatory reporting of manufacturing changes. This included chemistry, manufacturing, controls (CMC) changes requiring a new Investigational New Drug Application (IND) submission, and reporting manufacturing changes to an IND and to a Biologics License Application (BLA). Comparability assessment and reporting are also discussed, touching on risk assessment, analytical comparability study design, analytical methods, results, and statistics. There is also a section for special considerations for tissue-engineered medical products.
Due to the complexity of CGT products and the unique factors present in manufacturing and control of CGT products, making changes to their management and manufacturing may be more of a challenge than for other biological products. While product manufacturers may seek to make a manufacturing chance for many reasons, it is important that the risks to product quality be properly assessed beforehand. The guidance states, “Risk assessment should be performed for all types of manufacturing changes, regardless of the stage of product development. If a risk assessment indicates that a manufacturing change has the potential to adversely affect product quality, comparability studies should be performed to evaluate the impact of the proposed manufacturing change.”
Sponsors and applicants of CGT products were recommended to discuss significant manufacturing changes with FDA’s Center for Biologics Evaluation and Research, especially if the changes would take place in later stages of the product lifecycle.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
